"The findings presented today are evidence of how our approach of bringing together vast amounts of genetic and health information can shed light on the processes driving complex human traits. These SNPs offer a first step toward understanding the genetic component of AAM, and probably the timing of the onset of puberty in boys as well. But we have also been able to use them to confirm that overweight and obesity is linked to earlier AAM, and to suggest that later AAM contributes to greater height. The next step in this work is to look at how these and other new genetic factors linked to the timing of the reproductive cycle may be used to predict and prevent disease. We plan to incorporate the most interesting of today's findings into our deCODEme(TM) personal genome analysis service," said Kari Stefansson, CEO of deCODE and senior author on the paper.
The paper, "Genome-wide association study identifies sequence variants on 6q21 associated with age at menarche," is published in the online edition of Nature Genetics, at http://www.nature.com/ng, and will be published in an upcoming print edition of the journal.
deCODE is a bio-pharmaceutical company developing drugs and DNA-based
tests to improve the treatment, diagnosis and prevention of common diseases.
Its lead therapeutic programs, which leverage the company's expertise in
chemistry and structural biology, include DG041, an antiplatelet compound
being developed for the prevention of arterial thrombosis; DG051 and DG031,
compounds targeting the leukotriene pathway for the prevention of heart
attack; and DG071 and a platform for other PDE4 modulators with therapeutic
applications in Alzheimer's disease and other conditions. deCODE is a global
leader in human g
|SOURCE deCODE genetics Inc|
Copyright©2009 PR Newswire.
All rights reserved